

WHO HIV DRUG RESISTANCE REPORT 2012



WHO HIV DRUG RESISTANCE REPORT 2012

WHO Library Cataloguing-in-Publication Data

The HIV drug resistance report - 2012.

1.Anti-HIV agents – therapeutic use. 2.Drug resistance, Viral – drug effects. 3.HIV infections – epidemiology. 4.HIV infections – drug therapy 5.Population surveillance. 6.Sentinel surveillance. 7.Developing countries. 8.World health - statistics. I.World Health Organization.

ISBN 978 92 4 150393 8

(NLM classification: QV 268.5)

© World Health Organization 2012

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Design & layout: L'IV Com, Villars-sous-Yens, Switzerland

Printed in the USA

TABLE OF CONTENTS

Acronyms	2
Acknowledgements	3
Executive Summary	5
1. Introduction	9
1.1 Overview	9
1.2 Structure of the Report	9
1.3 Determinants of HIV drug resistance	9
1.3.1 Regimen- and drug-specific factors	9
1.3.2 Virus factors	10
1.3.3 Patient factors	10
1.3.4 Programmatic factors	10
1.4 WHO's global HIV drug resistance surveillance and monitoring strategy	11
1.5 Note on data sources and methods	12
2. HIV drug resistance in high-income countries	17
2.1 Drug resistance in ARV-naïve recently or chronically-infected populations	17
2.2 Acquired drug resistance	18
3. Transmitted HIV drug resistance in low- and middle-income countries	20
3.1 Overview	20
3.2 Literature review on drug resistance among ARV-naïve recently- or chronically-infected populations	20
3.3 WHO surveys to assess transmitted drug resistance	21
3.3.1 Overview	21
3.3.2 Classification of WHO surveys on transmitted HIV drug resistance	23
3.3.3 Pooled analysis	25
3.3.4 Prevalence of HIV drug resistance mutations	27
4. Acquired drug resistance in low- and middle-income countries	29
4.1 Overview	30
4.2 Literature review on acquired drug resistance in low- and middle-income countries	30
4.3 WHO surveys to assess acquired HIV drug resistance	30
4.3.1 Overview	31
4.3.2 Drug resistance before initiation of first-line antiretroviral therapy (survey baseline)	32
4.3.3 Acquired drug resistance among people failing first-line antiretroviral therapy at 12 months	35
4.3.3.1 Drug resistance in patients failing therapy at 12 months	37
4.3.3.2 Drug resistance prevention	37
4.3.3.3 Possible drug resistance	37
4.3.3.4 Prevalence and patterns of HIV drug resistance among people experiencing treatment failure 12 months after initiation	38
5. Early warning indicators	41
5.1 Overview	41
5.2 Revised early warning indicators and targets	43
6. Conclusions	45
Annexes	48
Annex 1 Methodological notes	48
Annex 2 Supplemental tables and figures	57

ACRONYMS

3TC	lamivudine
ABC	abacavir
ART	antiretroviral therapy
AZT	zidovudine
bPI	boosted protease inhibitors
CRF	circulating recombinant form
DNA	deoxyribonucleic acid
d4T	stavudine
ddI	didanosine
EFV	efavirenz
ETR	etravirine
FTC	emtricitabine
HIV	human immunodeficiency virus
NNRTI	non-nucleoside reverse-transcriptase inhibitor
NRTI	nucleoside reverse-transcriptase inhibitor
NVP	nevirapine
PCR	polymerase chain reaction
PI	protease inhibitors
PMTCT	prevention of mother-to-child transmission of HIV
PR	protease
RNA	ribonucleic acid
RPV	rilpivirine
RTI	reverse transcriptase inhibitor
RT-PCR	reverse-transcriptase polymerase chain reaction
SDRM	surveillance drug resistance mutation
TAM	thymidine analogue mutation
TDF	tenofovir

ACKNOWLEDGEMENTS

This report was produced by Silvia Bertagnolio (HIV Department, World Health Organization), Michael R. Jordan (HIV Department, World Health Organization), Jhoney Barcarolo (consultant) and Neil Parkin (consultant, Data First Consulting, Inc). Silvia Bertagnolio developed the analysis plan and provided overall coordination. All members of the core team contributed to the review, analysis and quality assurance of the data, writing and editing of the report and the preparation of figures and tables. Martina Penazzato assisted with research and review, and Adil Bahalim provided data management support. We thank Jos Perriens, coordinator of Technologies and Commodities Team, for reviewing drafts of this manuscript at various stages.

This work would not have been possible without the collaboration of national HIV programme managers and staff who supplied the surveillance data that underpins this report. Development and publication of this report were also supported by the generous financial contribution of the Bill and Melinda Gates Foundation. We are sincerely grateful to Christine Rousseau and Chris Duncombe for their continued support. We are indebted to Diane Bennett for her significant contribution to the development of the WHO HIV drug resistance surveillance and monitoring strategy, and to Karen Kelley, particularly for her important work on improving guidance and tools for early warning indicators.

We would also like to thank Annemarie Wensing, Elliot Raizes, Scott Hammer, Raph Hamers, Mark Wainberg (current chair of the HIVResNet), for reviewing the report and providing valuable comments on initial drafts; John Gregson, Daniel Davis, Andrew Phillips, and Valentina Cambiano for the statistical analysis; Daniel Davis and Ravi Gupta for their contribution on the systematic review of acquired and transmitted drug resistance; Andrea De Luca, Anna Hearps, Mark Wainberg, Scott Hammer, and Wataru Sugiura for contributing to the section of resistance in high-income countries; members of HIVResNet for their valuable inputs to develop the drug resistance survey methods, in particular to Mark Myatt and Don Sutherland; Annemarie Wensing and Anne-Mieke Vandamme, Jonathan Schapiro, Rami Kantor and Robert Shafer for their contribution to the interpretation of data from WHO surveys; and Tommy Liu, Robert Shafer, Anne-Mieke Vandamme, and Tulio de Oliveira for assistance with sequence analysis and drug resistance interpretations.

We sincerely thank Tobias F. Rinke de Wit, Raph Hamers and Kim Sigaloff for making available data from the PharmAccess African Studies to Evaluate Resistance (PASER), and the United States Centers for Disease Control and Prevention (CDC) for its contribution to the development and implementation of the HIV drug resistance strategy.

The laboratory members of the WHO HIVDR Network have been essential to the production of high-quality drug resistance surveillance data. The authors would like to thank Chunfu Yang (International Laboratory Branch, CDC/GAP, Atlanta), Martine Peeters (Laboratoire Rétrovirus IRD, Montpellier), and Paul Sandstrom (PHAC, Ottawa) for their support in genotyping specimens for the WHO HIV drug resistance surveys. In addition, the authors would like to thank all the other members of the network for producing high-quality surveillance data:

- Ramatou Toure and Christiane Adje (RETRO CI, Abidjan, Cote d'Ivoire)
- Almaz Abebe and Libsework Muluneh (HIV and Other Viral Disease Research, EHNRI, Addis Ababa, Ethiopia)
- Avelin Aghokeng (IMPM-IRD/CREMER, Yaounde, Cameroon)
- Clement Zeh (KEMRI/CDC HIV Research Laboratory, Kisumu, Kenya)
- Coumba Toure Kane and Souleymane Mboup (Bacteriology-Virology UTH A Le Dantec, Dakar, Senegal)
- Mariza Morgado and Jose Carlos Couto Fernandez (Laboratory of AIDS and Molecular Immunology, Oswaldo Cruz Foundation - FIOCRUZ, Rio de Janeiro, Brazil)
- Luke Hanna (Department of Clinical Research Tuberculosis Research Centre (ICMR), Chennai, India)
- Srikanth Tripathy and Ramesh Paranjape (National AIDS Research Institute, Indian Council of Medical Research, Pune, India)
- Siriphan Saeng-aroon (National Institute of Health, Department of Medical Sciences, Nonthaburi, Thailand)
- Ruengpung Sutthent (Dept Microbiology, Siriraj Hospital, Bangkok, Thailand)
- Shao Yiming (Division of Research on Virology and Immunology (DRVI), NCAIDS, Chinese Center for Disease Control and Prevention, Beijing, China)
- Ping Zhong (Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China)

-
- Hong Shang (Key Laboratory of Immunology of AIDS, Ministry of Health, Shenyang, China)
 - Gillian Hunt, Johanna Ledwaba, and Lynn Morris (AIDS VIRUS RESEARCH UNIT, National Institute for Communicable Diseases, Johannesburg, South Africa)
 - Chris Parry and Pontiano Kaleebu (MRC/UVRI Basic Sciences Laboratory, Entebbe, Uganda)
 - Georges Dos Santos (Service de Virologie Immunologie Centre Hospitalier et Universitaire de Fort-de-France, Fort-de-France, Martinique)
 - Anna Hearps, Vicki Edouard, Adele Lee-Wriede and Suzanne Crowe (Clinical Research Laboratory, Burnet Institute for Medical Research and Public Health, Melbourne, Australia)
 - Wendy Stevens (CLS Genotyping Laboratory, Johannesburg General Hospital, Johannesburg, South Africa)
 - Yasuhiro Yamamura (AIDS Research Program-Immunology Reference Laboratory, Ponce, Puerto Rico)
 - Leon McNally and Philip Cunningham (NSW State Reference Laboratory for HIV and Molecular Diagnostic Medicine, Sydney, Australia)
 - James Brooks (National Laboratory for HIV Genetics, PHAC, Ottawa, Canada)
 - Patricia Pinson and Herve Fleury (Laboratoire de Virologie, CHU, Bordeaux, France)
 - Rob Schuurman (Department Of Virology, University Medical Center Utrecht, Utrecht, Netherlands)
 - Carmen Mendoza and Vincente Soriano (Infectious Diseases Department, Hospital Carlos III, Madrid, Spain)
 - Pat Cane and Deenan Pillay (Health Protection Agency, London, United Kingdom)

We would also like to thank staff from WHO offices, including Emil Asamoah-Odei, Richard Banda, Fatim Cham, Christopher Dye, Guy-Michel Gershby-Damet, Noreen Jack, Patrick Kombate-Noudjo, Paul Assimawe Pana, Brian Pazvakavambwa, Giovanni Ravasi, Nirina Razakaso, Padmini Srikantiah and Dongbao Yu.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28385

